
Nice backs GSK’s lupus drug Benlysta
pharmafile | May 11, 2016 | News story | Research and Development, Sales and Marketing | GSK, NHS, NICE, regulation
The National Institute for Health and Care Excellence (Nice) has backed GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab) to treat lupus.
The regulator has recommended the drug on the condition the NHS England and the company work together to collect further data which addresses uncertainties about the efficacy of the drug.
The drug, Benlysta received the backing from the US Food and Drug Administration in 2011 for autoantibody-positive systemic lupus erythematosus. However, the UK regulators had held back recommendation saying the therapy did not represent a cost-effective use of resources.
Lupus is a chronic autoimmune disease that can lead to severe, debilitating symptoms, long-term organ damage and premature death. It affects more than 20,000 people in England and Wales, and some patients with advanced disease fail to respond to current therapy.
Anjali Shukla
Related Content

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC
Dr Zubir Ahmed MP, the Under-Secretary of State for Health Innovation and Safety, has visited …

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …






